Sinolink: Major policies have been released, innovation remains the most important direction. The pharmaceutical and healthcare Industry has entered a performance window, focusing on reversal expectations.

The market has entered the window period for annual and quarterly reports, and it is recommended to actively pay attention to the fundamental Bearish clearance of left-side symbols (such as some Medical Devices, Traditional Chinese Medicine, pharmacies, chain Medical, CXO, etc.) and the implementation of centralized procurement policies.

Zhitong Finance02:56 ET

SKB Biopharmaceutical Gets China Marketing Nod for Nasopharyngeal Cancer

MT NewswiresJan 2 03:38 ET

Hong Kong stock movement | SKB BIO-B (06990) is currently up over 4% as the National Medical Products Administration approves the launch of Tagrolimab injection.

SKB BIO-B (06990) rose over 4% in the morning session. As of the time of writing, it has increased by 4.53%, reaching 170.7 Hong Kong dollars, with a trading volume of 9.4408 million Hong Kong dollars.

Zhitong FinanceJan 1 20:46 ET

Announcement Highlights | The December Electric Vehicles sales report has been released! BYD sold 0.515 million vehicles in a month, and "Weixiaoli" reached new highs together; 13.138 billion Hong Kong dollars! Alibaba fully divested from SUNART RETAIL, a

GCL NEWENERGY plans to sell its photovoltaic assets in Micron; XINYI SOLAR's annual profit may drop by more than 70%.

cls.cnJan 1 19:42 ET

SKB BIO-B (06990.HK): Anti-PD-L1 Tagorelimab has been approved for marketing by the National Medical Products Administration.

Gelonghui, December 31st丨SKB BIO-B (06990.HK) announced that its innovative humanized monoclonal antibody targeting programmed cell death ligand 1 (PD-L1) known as Tagolisumab (formerly KL-A167) for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have previously failed second-line or above chemotherapy has been approved by the National Medical Products Administration (NMPA) in China for market release. This approval is primarily based on an open-label, multicenter, phase II clinical trial conducted in patients with recurrent or metastatic nasopharyngeal carcinoma who had previously experienced treatment failure after second-line or above systemic therapies.

Gelonghui FinanceDec 31, 2024 04:58 ET

Express News | Sichuan Kelun-Biotech Biopharmaceutical - Anti-Pd-L1 Tagitanlimab Approved for Marketing by Nmpa of China

ReutersDec 31, 2024 04:56 ET